Literature DB >> 28067895

The NF1 gene in tumor syndromes and melanoma.

Maija Kiuru1, Klaus J Busam2.   

Abstract

Activation of the RAS/MAPK pathway is critical in melanoma. Melanoma can be grouped into four molecular subtypes based on their main genetic driver: BRAF-mutant, NRAS-mutant, NF1-mutant, and triple wild-type tumors. The NF1 protein, neurofibromin 1, negatively regulates RAS proteins through GTPase activity. Germline mutations in NF1 cause neurofibromatosis type I, a common genetic tumor syndrome caused by dysregulation of the RAS/MAPK pathway, ie, RASopathy. Melanomas with NF1 mutations typically occur on chronically sun-exposed skin or in older individuals, show a high mutation burden, and are wild-type for BRAF and NRAS. Additionally, NF1 mutations characterize certain clinicopathologic melanoma subtypes, specifically desmoplastic melanoma. This review discusses the current knowledge of the NF1 gene and neurofibromin 1 in neurofibromatosis type I and in melanoma.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28067895      PMCID: PMC5413358          DOI: 10.1038/labinvest.2016.142

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  113 in total

1.  Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes.

Authors:  Christian P Kratz; Suthee Rapisuwon; Helen Reed; Henrik Hasle; Philip S Rosenberg
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-04-15       Impact factor: 3.908

2.  BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.

Authors:  Victoria J Mar; Stephen Q Wong; Jason Li; Richard A Scolyer; Catriona McLean; Anthony T Papenfuss; Richard W Tothill; Hojabr Kakavand; Graham J Mann; John F Thompson; Andreas Behren; Jonathan S Cebon; Rory Wolfe; John W Kelly; Alexander Dobrovic; Grant A McArthur
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

3.  The NF1 tumor suppressor critically regulates TSC2 and mTOR.

Authors:  Cory M Johannessen; Elizabeth E Reczek; Marianne F James; Hilde Brems; Eric Legius; Karen Cichowski
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-03       Impact factor: 11.205

4.  Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus.

Authors:  D Viskochil; A M Buchberg; G Xu; R M Cawthon; J Stevens; R K Wolff; M Culver; J C Carey; N G Copeland; N A Jenkins
Journal:  Cell       Date:  1990-07-13       Impact factor: 41.582

5.  Elevated risk for MPNST in NF1 microdeletion patients.

Authors:  T De Raedt; H Brems; P Wolkenstein; D Vidaud; S Pilotti; F Perrone; V Mautner; S Frahm; R Sciot; E Legius
Journal:  Am J Hum Genet       Date:  2003-03-26       Impact factor: 11.025

Review 6.  Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways.

Authors:  Daniela Katz; Alexander Lazar; Dina Lev
Journal:  Expert Rev Mol Med       Date:  2009-10-19       Impact factor: 5.600

7.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

8.  Multipoint linkage analysis in neurofibromatosis type I: an international collaboration.

Authors:  D E Goldgar; P Green; D M Parry; J J Mulvihill
Journal:  Am J Hum Genet       Date:  1989-01       Impact factor: 11.025

9.  Mutation spectrum of NF1 and clinical characteristics in 78 Korean patients with neurofibromatosis type 1.

Authors:  Jung Min Ko; Young Bae Sohn; Seon Yong Jeong; Hyon-Ju Kim; Ludwine M Messiaen
Journal:  Pediatr Neurol       Date:  2013-06       Impact factor: 3.372

10.  Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.

Authors:  Michael Krauthammer; Yong Kong; Antonella Bacchiocchi; Perry Evans; Natapol Pornputtapong; Cen Wu; Jamie P. McCusker; Shuangge Ma; Elaine Cheng; Robert Straub; Merdan Serin; Marcus Bosenberg; Stephan Ariyan; Deepak Narayan; Mario Sznol; Harriet M Kluger; Shrikant Mane; Joseph Schlessinger; Richard P Lifton; Ruth Halaban
Journal:  Nat Genet       Date:  2015-07-27       Impact factor: 41.307

View more
  56 in total

1.  Translating Nanomedicine to Comparative Oncology-the Case for Combining Zinc Oxide Nanomaterials with Nucleic Acid Therapeutic and Protein Delivery for Treating Metastatic Cancer.

Authors:  R K DeLong; Yi-Hsien Cheng; Paige Pearson; Zhoumeng Lin; Calli Coffee; Elza Neelima Mathew; Amanda Hoffman; Raelene M Wouda; Mary Lynn Higginbotham
Journal:  J Pharmacol Exp Ther       Date:  2019-04-30       Impact factor: 4.030

2.  Computational insights of K1444N substitution in GAP-related domain of NF1 gene associated with neurofibromatosis type 1 disease: a molecular modeling and dynamics approach.

Authors:  Ashish Kumar Agrahari; Meghana Muskan; C George Priya Doss; R Siva; Hatem Zayed
Journal:  Metab Brain Dis       Date:  2018-05-27       Impact factor: 3.584

3.  Genomic alterations in advanced gastric cancer endoscopic biopsy samples using targeted next-generation sequencing.

Authors:  Sai Ge; Beifang Li; Yanyan Li; Zhongwu Li; Zhentao Liu; Zuhua Chen; Jian Wu; Jing Gao; Lin Shen
Journal:  Am J Cancer Res       Date:  2017-07-01       Impact factor: 6.166

Review 4.  Signal pathways of melanoma and targeted therapy.

Authors:  Weinan Guo; Huina Wang; Chunying Li
Journal:  Signal Transduct Target Ther       Date:  2021-12-20

Review 5.  Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2017-11-20

Review 6.  Aldehyde dehydrogenase-positive melanoma stem cells in tumorigenesis, drug resistance and anti-neoplastic immunotherapy.

Authors:  Simin Zhang; Zhen Yang; Fazhi Qi
Journal:  Mol Biol Rep       Date:  2019-12-14       Impact factor: 2.316

7.  Recurrent vulvar melanoma in a patient with neurofibromatosis and gastrointestinal stromal tumour.

Authors:  Anna Linehan; Emily Harrold; Keith Pilson; John McCaffrey
Journal:  BMJ Case Rep       Date:  2019-01-20

8.  Surgical management of peripheral nerve sheath tumours in children, with special consideration of neurofibromatoses.

Authors:  Julian Zipfel; Meizer Al-Hariri; Isabel Gugel; Karin Haas-Lude; Alexander Grimm; Steven Warmann; Michael Krimmel; Victor-Felix Mautner; Marcos Tatagiba; Martin U Schuhmann
Journal:  Childs Nerv Syst       Date:  2020-06-06       Impact factor: 1.475

Review 9.  The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated Melanoma.

Authors:  Elizabeth L Thompson; Jiayi J Hu; Laura J Niedernhofer
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

Review 10.  Aetiology and Pathogenesis of Cutaneous Melanoma: Current Concepts and Advances.

Authors:  Strahil Strashilov; Angel Yordanov
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.